Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire December 08, 2025 WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of […]

Meridian Mining Announces Corporate Updates

London, United Kingdom–(Newsfile Corp. – December 8, 2025) – Meridian Mining Plc (TSX: MNO) (FSE: N2E) (OTCQX: MRRDF) (“Meridian” or the “Company”) is pleased to announce that Mr. David Halkyard has been appointed as the Company’s Chief Financial Officer (“CFO”) effective November 25, 20251. In addition, the Company announces the appointment of Ms. Catherine Apthorpe

Avanti Gold Announces OTCQB Venture Market Eligibility

Vancouver, British Columbia–(Newsfile Corp. – December 8, 2025) – Avanti Gold Corp. (CSE: AGC) (FSE: X370) (OTCQB: AVTGF) (“Avanti” or the “Company“) is pleased to report that its common shares will begin trading on the OTCQB Venture Market (the “OTCQB”) in the United States under the ticker symbol AVTGF on December 8, 2025. The Company’s

Marquis Software Solutions, Inc./Norway Savings Bank Data Breach Alert Issued By Wolf Haldenstein

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”),a preeminent national consumer rights law firm, is investigating claims on behalf of people who have been impacted by the Marquis Software Solutions, Inc. (“Marquis”) data breach. https://mma.prnewswire.com/media/1064977/Wolf_Haldenstein_Adler_Freeman_Logo.jpg Marquis, located in Plano, Texas, is a vendor of Norway Savings

Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is January 9, 2026 Wolf Haldenstein Adler Freeman & Herz LLPreminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)(“Telix”) American Depositary Shares (“ADS”) that a securities class action has been filed. The class period is between February 21, 2025 and August 28, 2025, inclusive. Investors have until January 9, 2026to seek

Shareholders who lost money in shares of Alexandria Real Estate Equities, Inc. (NYSE: ARE) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is January 26, 2026 WolfHaldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Alexandria Real Estate Equities, Inc. (NYSE: ARE) (“Alexandria”) that a federal securities class action has been filed on behalf of investors who purchased Alexandria between January 27, 2025 and October 27, 2025, inclusive (the “Class Period”). Investors

Shareholders who lost money in shares of Jayud Global Logistics Limited (NASDAQ : JYD) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is January 20, 2026 Wolf Haldenstein Adler Freeman & Herz LLPreminds purchasers or acquirers of Jayud Global Logistics Limited (NASDAQ: JYD) (“Jayud”) that a federal securities class action has been filed in the United States District Court for the Southern District of New York. The action is filed against Jayud Global Logistics

Shareholders who lost money in shares of Inspire Medical Systems, Inc. (NYSE: INSP) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is January 5, 2026 Wolf Haldenstein Adler Freeman & Herz LLPinforms investors in Inspire Medical Systems, Inc. (NYSE: INSP)(“Inspire”)that a securities class action has been filed on behalf of all those who purchased shares between August 6, 2024 and August 4, 2025 (the “Class Period”). Investors have until January 5, 2026 to

Kymera Therapeutics Announces Proposed Public Offering

(NasdaqGM:KYMR), WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

(NasdaqGM:GPCR), SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million

Scroll to Top